GLP-1 medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and their compounded alternatives — have become the most commercially significant pharmaceutical category of the decade, with an estimated 15 million Americans currently taking some form of GLP-1 agonist and millions more entering the category each year. The appetite-suppressing effect of these medications has created a specific and previously unaddressed nutritional challenge: eating meaning